The effects of non-prostaglandin hypotensive drops with preservative on central retinal thickness after phacoemulsification

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Primary open angle glaucoma is often associated with cataract. The correlation between the use hypotensive drops, in particular non-prostaglandin hypotensive drops with preservative, and the change in central retinal thickness after phacoemulsification with intraocular lens implantation continues to be relevant.

AIM: To evaluate central retinal thickness and pseudophakic cystoid macular edema incidence after phacoemulsification with intraocular lens implantation in patients with primary open-angle glaucoma using non-prostaglandin hypotensive drops with preservatives.

MATERIALS AND METHODS: 94 patients (108 eyes) with cataract were enrolled in the study, divided into 3 groups: the first group — 21 patients (27 eyes), and the second group — 21 patients (23 eyes) with primary open-angle glaucoma using non-prostaglandin hypotensive drops with preservative; the third (control) group included 52 patients (58 eyes) without ocular comorbidities. All patients underwent uncomplicated phacoemulsification with intraocular lens implantation. In the post-op period, patients of the first group received topical antibiotics and steroids, patients of the second and the third groups received the same treatment and non-steroidal anti-inflammatory drops as well. Central retinal thickness was measured using optical coherence tomography before surgery, 2 weeks, 2 and 6 months after surgery.

RESULTS: The central retinal thickness increase in comparison with baseline values was more significant in the first group than in the second and the third groups, and the time of recovery to baseline values during 6 months after surgery was longer. Pseudophakic cystoid macular edema was not identified in any group.

CONCLUSIONS: The use non-prostaglandin drops with preservative in patients with primary open-angle glaucoma does not affect pseudophakic cystoid macular edema development after uncomplicated phacoemulsification. Instillations of non-steroidal anti-inflammatory drops in the post-op period reduce the time of central retinal thickness recovery to baseline value.

About the authors

Xiaoyuan Wang

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: wangxiaoyuan20121017@gmail.com
ORCID iD: 0000-0002-1135-6796

postgraduate student of Department of Ophthalmology with Clinic

Russian Federation, Saint Petersburg

Sergey Yu. Astakhov

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: astakhov73@mail.ru
ORCID iD: 0000-0003-0777-4861
SPIN-code: 7732-1150
Scopus Author ID: 56660518500

MD, Dr. Sci. (Med.), professor, head of Department of Ophthalmology with Clinic

Russian Federation, Saint Petersburg

Anna S. Cherkashina

City Multidisciplinary Hospital No. 2

Author for correspondence.
Email: annaa.cherkashina@mail.ru
ORCID iD: 0009-0006-3837-7382

ophthalmologist in 5th Microsurgical Ophthalmology Department

Russian Federation, Saint Petersburg

Liliia K. Anikina

Academician I.P. Pavlov First St. Petersburg State Medical University; City Multidisciplinary Hospital No. 2

Email: lily-sai@yandex.ru
ORCID iD: 0000-0001-8794-0457
SPIN-code: 3359-4587

postgraduate student of Department of Ophthalmology with Clinic; ophthalmologist in Microsurgical (laser) Department

Russian Federation, Saint Petersburg; Saint Petersburg

Tat’yana R. Parasun’ko

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: exclamation@bk.ru
ORCID iD: 0000-0003-4533-7590
SPIN-code: 4362-6730

medical resident of Department of Ophthalmology with Clinic

Russian Federation, Saint Petersburg

Vitaliy V. Potemkin

Academician I.P. Pavlov First St. Petersburg State Medical University; City Multidisciplinary Hospital No. 2

Email: potem@inbox.ru
ORCID iD: 0000-0001-7807-9036
SPIN-code: 3132-9163

Cand. Sci. (Med.), assistant professor of Department of Ophthalmology with Clinic; head of 5th Microsurgical Ophthalmology Department

Russian Federation, Saint Petersburg; Saint Petersburg

Albina R. Potemkina

City Multidisciplinary Hospital No. 2

Email: prinzabiyka@mail.ru

ophthalmologist in Microsurgical (laser) Department

Russian Federation, Saint Petersburg

References

  1. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002;47(S1):S203–S218. doi: 10.1016/s0039-6257(02)00294-1
  2. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105(2):263–268. doi: 10.1016/s0161-6420(98)92977-3
  3. Lima MC, Paranhos A Jr, Salim S, et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000;9(4):317–321. doi: 10.1097/00061198-200008000-00006
  4. Michels RG, Maumenee AE. Cystoid macular edema associated with topically applied epinephrine in aphakic eyes. Am J Ophthalmol. 1975;80(3):379–388. doi: 10.1016/0002-9394(75)90522-x
  5. Kolker AE, Becker B. Epinephrine maculopathy. Arch Ophthalmol. 1968;79(5):552–562. doi: 10.1001/archopht.1968.03850040554010
  6. Mehelas TJ, Kollarits CR, Martin WG. Cystoid macular edema presumably induced by dipivefrin hydrochloride (Propine). Am J Ophthalmol. 1982;94(5):682. doi: 10.1016/0002-9394(82)90019-8
  7. Hesse RJ, Swan JL. Aphakic cystoid macular edema secondary to betaxolol therapy. Ophthalmic Surg Lasers Imaging Retina. 1988;19(8):562–564. doi: 10.3928/1542-8877-19880801-10
  8. Kim P, Lertsumitkul S. Cystoid macular oedema associated with brimonidine therapy. Clin Exp Ophthalmol. 2003;31(2):165–166. doi: 10.1046/j.1442-9071.2003.00628.x
  9. Miyake K, Octa I, Ibaraki N, et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001;119(3):387–394. doi: 10.1001/archopht.119.3.387
  10. Astakhov SY, Astakhov YS, Gobedzhishvili MV. The influence of prostaglandin analogs on the retinal thickness after phacoemulsification with intraocular lens implantation in primary open-angle glaucoma patients. Ophthalmology Reports. 2014;7(3):73–76. (In Russ.) doi: 10.17816/OV2014373-76
  11. Irvine SR. A newly defined vitreous syndrome following cataract surgery: Interpreted according to recent concepts of the structure of the vitreous. The seventh Francis I. Proctor Lecture. Am J Ophthalmol. 1953;36(5):599–619. doi: 10.1016/0002-9394(53)90302-x
  12. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557–634.
  13. Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8): 1446–1449. doi: 10.1016/j.ophtha.2006.03.027
  14. Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123(2):316–323. doi: 10.1016/j.ophtha.2015.10.001
  15. Rotsos TG, Moschos MM. Cystoid macular edema. Clin Ophthalmol. 2008;2(4):919–930. doi: 10.2147/opth.s4033
  16. Kokorev VL. The analysis of risk factors of development of macular edema after phacoemulsification. Ophthalmology in Russia. 2019;16(2):185–191. (In Russ.) doi: 10.18008/1816-5095-2019-2-185-191
  17. Shah N, Maguire MG, Martin DF, et al. Angiographic cystoid macular edema and outcomes in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(4):858–864. doi: 10.1016/j.ophtha.2015.11.030
  18. Hajali M, Fishman GA, Anderson RJ. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol. 2008;92(8):1065–1068. doi: 10.1136/bjo.2008.138560
  19. Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc. 2005;103:537–567.
  20. Henderson BA, Kim JY, Ament CS, et al. Clinical pseudophakic cystoid macular edema: risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33(9):1550–1558. doi: 10.1016/j.jcrs.2007.05.013
  21. Schaub F, Adler W, Enders P, et al. Preexisting epiretinal membrane is associated with pseudophakic cystoid macular edema. Graefe’s Arch Clin Exp Ophthalmol. 2018;256:909–917. doi: 10.1007/s00417-018-3954-4
  22. Wendel C, Zakrzewski H, Carleton B, et al. Association of postoperative topical prostaglandin analog or beta-blocker use and incidence of pseudophakic cystoid macular edema. J Glaucoma. 2018;27(5):402–406. doi: 10.1097/IJG.0000000000000929
  23. Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Int Med. 2012;172(13):1005–1011. doi: 10.1001/archinternmed.2012.1938
  24. Yokoe T, Fukada I, Kobayashi K, et al. Cystoid macular edema during treatment with paclitaxel and bevacizumab in a patient with metastatic breast cancer: a case report and literature review. Case Rep Oncol. 2017;10(2):605–612. doi: 10.1159/000477897
  25. Gass JDM. Nicotinic acid maculopathy. Am J Ophthalmol. 1973;76(4):500–510. doi: 10.1016/0002-9394(73)90738-1
  26. Millay RH, Klein ML, Illingworth DR. Niacin maculopathy. Ophthalmology. 1988;95(7):930–936. doi: 10.1016/s0161-6420(88)33073-3
  27. Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol. 1995;79(1):54–56. doi: 10.1136/bjo.79.1.54
  28. Callanan D, Blodi BA, Martin DF. Macular edema associated with nicotinic acid (niacin). JAMA. 1998;279(21):1702–1702. doi: 10.1001/jama.279.21.1702-b
  29. Domanico D, Verboschi F, Altimari S, et al. Ocular effects of niacin: a review of the literature. Med Hypothesis Discov Innov Ophthalmol. 2015;4(2):64–71.
  30. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78(9):672–680. doi: 10.1212/WNL.0b013e318248deea
  31. Lee KM, Lee EJ, Kim T-W, Kim H. Pseudophakic macular edema in primary open-angle glaucoma: a prospective study using spectral-domain optical coherence tomography. Am J Ophthalmol. 2017;179:97–109. doi: 10.1016/j.ajo.2017.05.001
  32. Williams DE, Nguyen KD, Shapourifar-Tehrani S, et al. Effects of timolol, betaxolol, and levobunolol on human tenon’s fibroblasts in tissue culture. Investig Ophthalmol Vis Sci. 1992;33(7):2233–2241.
  33. Baudouin C, Pisella P-J, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106(3):556–563. doi: 10.1016/S0161-6420(99)90116-1
  34. Miyake K, Ibaraki N, Goto Y, et al. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003;29(9):1800–1810. doi: 10.1016/s0886-3350(03)00560-1
  35. Sánchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, et al. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci. 2002;43(5):1588–1594.
  36. von Jagow B, Ohrloff C, Kohnen T. Macular thickness after uneventful cataract surgery determined by optical coherence tomography. Graefe’s Arch Clin Exp Ophthalmol. 2007;245:1765–1771. doi: 10.1007/s00417-007-0605-6
  37. Perente I, Utine CA, Ozturker C, et al. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr Eye Res. 2007;32(3):241–247. doi: 10.1080/02713680601160610
  38. Ching H-Y, Wong AC, Wong C-C, et al. Cystoid macular oedema and changes in retinal thickness after phacoemulsification with optical coherence tomography. Eye. 2006;20(3):297–303. doi: 10.1038/sj.eye.6701864
  39. Wang X, Astakhov SY, Potemkin VV, et al. Evaluation of retinal thickness and of pseudophakic cystoid macular edema incidence in patients with primary open-angle glaucoma treated with prostaglandin analogues. Ophthalmology Reports. 2021;14(2):17–26. (In Russ.) doi: 10.17816/OV64116
  40. Kurt A, Kılıç R. The effects of uncomplicated cataract surgery on retinal layer thickness. J Ophthalmol. 2018;2018:7218639. doi: 10.1155/2018/7218639
  41. Cagini C, Fiore T, Laccheri B, et al. Macular thickness measured by optical coherence tomography in a healthy population before and after uncomplicated cataract phacoemulsification surgery. Curr Eye Res. 2009;34(12):1036–1041. doi: 10.3109/02713680903288937
  42. Falcão MS, Gonçalves N, Freitas-Costa P, et al. Choroidal and macular thickness changes induced by cataract surgery. Clin Ophthalmol. 2013;8:55–60. doi: 10.2147/OPTH.S53989

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. The pathogenesis of “pseudophakic preservative maculopathy” by K. Miyake [35]

Download (214KB)
Indexing metadata
3. Fig. 2. Analysis of medications used in the first group (non-prostaglandin hypotensive drops with preservative)

Download (91KB)
Indexing metadata
4. Fig. 3. Analysis of medications used in the second group (non-prostaglandin hypotensive drops with preservative + nonsteroidal anti-inflammatory drops)

Download (110KB)
Indexing metadata
5. Fig. 4. Dynamics of the central retinal thickness change in studied groups

Download (125KB)
Indexing metadata
6. Fig. 5. Dynamics of the central retinal thickness change in studied groups compared to preoperative values at different observation periods

Download (99KB)
Indexing metadata

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».